Combination of EGFR-TKI and Chemotherapy Versus EGFR-TKI Monotherapy as Neoadjuvant Treatment of Stage III-N2 EGFR-Mutant Non-Small Cell Lung Cancer
CONCLUSION: Combination therapy with first-generation EGFR-TKI and chemotherapy could be considered a neoadjuvant treatment option for patients with stage III-N2 EGFR-mutant NSCLC, exhibiting acceptable toxicity. However, regarding short-term efficacy, combination therapy did not demonstrate superiority over EGFR-TKI monotherapy. Long-term follow-up is warranted for a more accurate assessment of the DFS and OS.PMID:38529688 | DOI:10.1093/oncolo/oyae052
Source: The Oncologist - Category: Cancer & Oncology Authors: Yingqi Xu Hao Ji Yidan Zhang Liwen Xiong Baohui Han Hua Zhong Jianlin Xu Runbo Zhong Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Non-Small Cell Lung Cancer | Study | Toxicology